Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

Sorted by: relevance · author · university · dateNew search

You searched for +publisher:"Clemson University" +contributor:("Chen, Wen Y"). Showing records 1 – 6 of 6 total matches.

Search Limiters

Last 2 Years | English Only

No search limiters apply to these results.

▼ Search Limiters


Clemson University

1. Xu, Cong. STROMAL-EPITHELIAL INTERACTIONS MODULATE CROSS TALK BETWEEN PROLACTIN RECEPTOR AND HER2/NEU IN BREAST CANCER.

Degree: PhD, Biological Sciences, 2012, Clemson University

 The tumor microenvironment is a crucial factor in breast tumorigenesis. Tumor epithelial cells maintain 3D structure in tumor stroma and they interact with soluble factors… (more)

Subjects/Keywords: Breast Cancer; Crosstalk; G129R; HER2; Prolactin; Tumor Microenvironment; Molecular Biology

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Xu, C. (2012). STROMAL-EPITHELIAL INTERACTIONS MODULATE CROSS TALK BETWEEN PROLACTIN RECEPTOR AND HER2/NEU IN BREAST CANCER. (Doctoral Dissertation). Clemson University. Retrieved from https://tigerprints.clemson.edu/all_dissertations/918

Chicago Manual of Style (16th Edition):

Xu, Cong. “STROMAL-EPITHELIAL INTERACTIONS MODULATE CROSS TALK BETWEEN PROLACTIN RECEPTOR AND HER2/NEU IN BREAST CANCER.” 2012. Doctoral Dissertation, Clemson University. Accessed July 18, 2019. https://tigerprints.clemson.edu/all_dissertations/918.

MLA Handbook (7th Edition):

Xu, Cong. “STROMAL-EPITHELIAL INTERACTIONS MODULATE CROSS TALK BETWEEN PROLACTIN RECEPTOR AND HER2/NEU IN BREAST CANCER.” 2012. Web. 18 Jul 2019.

Vancouver:

Xu C. STROMAL-EPITHELIAL INTERACTIONS MODULATE CROSS TALK BETWEEN PROLACTIN RECEPTOR AND HER2/NEU IN BREAST CANCER. [Internet] [Doctoral dissertation]. Clemson University; 2012. [cited 2019 Jul 18]. Available from: https://tigerprints.clemson.edu/all_dissertations/918.

Council of Science Editors:

Xu C. STROMAL-EPITHELIAL INTERACTIONS MODULATE CROSS TALK BETWEEN PROLACTIN RECEPTOR AND HER2/NEU IN BREAST CANCER. [Doctoral Dissertation]. Clemson University; 2012. Available from: https://tigerprints.clemson.edu/all_dissertations/918


Clemson University

2. Jacquemart, Isabelle. Identification of the Rassf3 Gene as a Potential Tumor Suppressor Responsible for the Resistance to Mammary Tumor Development in MMTV/neu Transgenic Mice.

Degree: PhD, Microbiology, 2006, Clemson University

 The MMTV/neu transgenic mouse line is a well-documented animal model for studying HER2/neu-related breast cancer. It has been reported that a small percentage, approximately 20%,… (more)

Subjects/Keywords: Breast Cancer Research; Microbiology

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Jacquemart, I. (2006). Identification of the Rassf3 Gene as a Potential Tumor Suppressor Responsible for the Resistance to Mammary Tumor Development in MMTV/neu Transgenic Mice. (Doctoral Dissertation). Clemson University. Retrieved from https://tigerprints.clemson.edu/all_dissertations/26

Chicago Manual of Style (16th Edition):

Jacquemart, Isabelle. “Identification of the Rassf3 Gene as a Potential Tumor Suppressor Responsible for the Resistance to Mammary Tumor Development in MMTV/neu Transgenic Mice.” 2006. Doctoral Dissertation, Clemson University. Accessed July 18, 2019. https://tigerprints.clemson.edu/all_dissertations/26.

MLA Handbook (7th Edition):

Jacquemart, Isabelle. “Identification of the Rassf3 Gene as a Potential Tumor Suppressor Responsible for the Resistance to Mammary Tumor Development in MMTV/neu Transgenic Mice.” 2006. Web. 18 Jul 2019.

Vancouver:

Jacquemart I. Identification of the Rassf3 Gene as a Potential Tumor Suppressor Responsible for the Resistance to Mammary Tumor Development in MMTV/neu Transgenic Mice. [Internet] [Doctoral dissertation]. Clemson University; 2006. [cited 2019 Jul 18]. Available from: https://tigerprints.clemson.edu/all_dissertations/26.

Council of Science Editors:

Jacquemart I. Identification of the Rassf3 Gene as a Potential Tumor Suppressor Responsible for the Resistance to Mammary Tumor Development in MMTV/neu Transgenic Mice. [Doctoral Dissertation]. Clemson University; 2006. Available from: https://tigerprints.clemson.edu/all_dissertations/26


Clemson University

3. Kotturi rajeshwar, Hari shankar. CONSTRUCTION AND CHARACTERIZATION OF A NOVEL FUSION PROTEIN FROM THE EXTRACELLULAR DOMAIN OF MULT1 AND TRANSMEMBRANE AND INTRACELLULAR DOMAINS OF FAS AND ITS THERAPEUTIC EVALUATION FOR CANCER TREATMENT USING AN ADENOVIRAL DELIVERY SYSTEM.

Degree: PhD, Microbiology, 2009, Clemson University

 One of the strategies that tumor cells adopt to evade immunosurveillance mounted by elements of the innate immune system, such as NK cells, is to… (more)

Subjects/Keywords: Adenovirus; Fas; Fusion Protein; Gene Therapy; MULT1; NKG2D; Cell Biology

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Kotturi rajeshwar, H. s. (2009). CONSTRUCTION AND CHARACTERIZATION OF A NOVEL FUSION PROTEIN FROM THE EXTRACELLULAR DOMAIN OF MULT1 AND TRANSMEMBRANE AND INTRACELLULAR DOMAINS OF FAS AND ITS THERAPEUTIC EVALUATION FOR CANCER TREATMENT USING AN ADENOVIRAL DELIVERY SYSTEM. (Doctoral Dissertation). Clemson University. Retrieved from https://tigerprints.clemson.edu/all_dissertations/370

Chicago Manual of Style (16th Edition):

Kotturi rajeshwar, Hari shankar. “CONSTRUCTION AND CHARACTERIZATION OF A NOVEL FUSION PROTEIN FROM THE EXTRACELLULAR DOMAIN OF MULT1 AND TRANSMEMBRANE AND INTRACELLULAR DOMAINS OF FAS AND ITS THERAPEUTIC EVALUATION FOR CANCER TREATMENT USING AN ADENOVIRAL DELIVERY SYSTEM.” 2009. Doctoral Dissertation, Clemson University. Accessed July 18, 2019. https://tigerprints.clemson.edu/all_dissertations/370.

MLA Handbook (7th Edition):

Kotturi rajeshwar, Hari shankar. “CONSTRUCTION AND CHARACTERIZATION OF A NOVEL FUSION PROTEIN FROM THE EXTRACELLULAR DOMAIN OF MULT1 AND TRANSMEMBRANE AND INTRACELLULAR DOMAINS OF FAS AND ITS THERAPEUTIC EVALUATION FOR CANCER TREATMENT USING AN ADENOVIRAL DELIVERY SYSTEM.” 2009. Web. 18 Jul 2019.

Vancouver:

Kotturi rajeshwar Hs. CONSTRUCTION AND CHARACTERIZATION OF A NOVEL FUSION PROTEIN FROM THE EXTRACELLULAR DOMAIN OF MULT1 AND TRANSMEMBRANE AND INTRACELLULAR DOMAINS OF FAS AND ITS THERAPEUTIC EVALUATION FOR CANCER TREATMENT USING AN ADENOVIRAL DELIVERY SYSTEM. [Internet] [Doctoral dissertation]. Clemson University; 2009. [cited 2019 Jul 18]. Available from: https://tigerprints.clemson.edu/all_dissertations/370.

Council of Science Editors:

Kotturi rajeshwar Hs. CONSTRUCTION AND CHARACTERIZATION OF A NOVEL FUSION PROTEIN FROM THE EXTRACELLULAR DOMAIN OF MULT1 AND TRANSMEMBRANE AND INTRACELLULAR DOMAINS OF FAS AND ITS THERAPEUTIC EVALUATION FOR CANCER TREATMENT USING AN ADENOVIRAL DELIVERY SYSTEM. [Doctoral Dissertation]. Clemson University; 2009. Available from: https://tigerprints.clemson.edu/all_dissertations/370


Clemson University

4. Park, Jang pyo. Characterization of the Anti-angiogenic Properties of KDR-Ig4-7 and its Variants as Potential Anti-cancer Therapeutics.

Degree: PhD, Microbiology, 2007, Clemson University

 Beginning with the development of an embryo and throughout one's adult life angiogenesis plays an essential role for organ growth and repair. The balancing of… (more)

Subjects/Keywords: angiogenesis; anti-angiogenesis; VEGF; VEGFR-2; KDR; cancer; Oncology

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Park, J. p. (2007). Characterization of the Anti-angiogenic Properties of KDR-Ig4-7 and its Variants as Potential Anti-cancer Therapeutics. (Doctoral Dissertation). Clemson University. Retrieved from https://tigerprints.clemson.edu/all_dissertations/161

Chicago Manual of Style (16th Edition):

Park, Jang pyo. “Characterization of the Anti-angiogenic Properties of KDR-Ig4-7 and its Variants as Potential Anti-cancer Therapeutics.” 2007. Doctoral Dissertation, Clemson University. Accessed July 18, 2019. https://tigerprints.clemson.edu/all_dissertations/161.

MLA Handbook (7th Edition):

Park, Jang pyo. “Characterization of the Anti-angiogenic Properties of KDR-Ig4-7 and its Variants as Potential Anti-cancer Therapeutics.” 2007. Web. 18 Jul 2019.

Vancouver:

Park Jp. Characterization of the Anti-angiogenic Properties of KDR-Ig4-7 and its Variants as Potential Anti-cancer Therapeutics. [Internet] [Doctoral dissertation]. Clemson University; 2007. [cited 2019 Jul 18]. Available from: https://tigerprints.clemson.edu/all_dissertations/161.

Council of Science Editors:

Park Jp. Characterization of the Anti-angiogenic Properties of KDR-Ig4-7 and its Variants as Potential Anti-cancer Therapeutics. [Doctoral Dissertation]. Clemson University; 2007. Available from: https://tigerprints.clemson.edu/all_dissertations/161


Clemson University

5. Langenheim, John. DEVELOPMENT OF NOVEL PROLACTIN AND GROWTH HORMONE RECEPTOR AGONISTS AND ANTAGONISTS.

Degree: PhD, Microbiology, 2007, Clemson University

  Potential indications for human prolactin (hPRL) and human growth hormone (hGH) are the support and sustainment of lactation and the enhancement or reconstitution of… (more)

Subjects/Keywords: prolactin; growth hormone; breast cancer; antagonist; fusion toxin; albumin binding; Molecular Biology

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Langenheim, J. (2007). DEVELOPMENT OF NOVEL PROLACTIN AND GROWTH HORMONE RECEPTOR AGONISTS AND ANTAGONISTS. (Doctoral Dissertation). Clemson University. Retrieved from https://tigerprints.clemson.edu/all_dissertations/157

Chicago Manual of Style (16th Edition):

Langenheim, John. “DEVELOPMENT OF NOVEL PROLACTIN AND GROWTH HORMONE RECEPTOR AGONISTS AND ANTAGONISTS.” 2007. Doctoral Dissertation, Clemson University. Accessed July 18, 2019. https://tigerprints.clemson.edu/all_dissertations/157.

MLA Handbook (7th Edition):

Langenheim, John. “DEVELOPMENT OF NOVEL PROLACTIN AND GROWTH HORMONE RECEPTOR AGONISTS AND ANTAGONISTS.” 2007. Web. 18 Jul 2019.

Vancouver:

Langenheim J. DEVELOPMENT OF NOVEL PROLACTIN AND GROWTH HORMONE RECEPTOR AGONISTS AND ANTAGONISTS. [Internet] [Doctoral dissertation]. Clemson University; 2007. [cited 2019 Jul 18]. Available from: https://tigerprints.clemson.edu/all_dissertations/157.

Council of Science Editors:

Langenheim J. DEVELOPMENT OF NOVEL PROLACTIN AND GROWTH HORMONE RECEPTOR AGONISTS AND ANTAGONISTS. [Doctoral Dissertation]. Clemson University; 2007. Available from: https://tigerprints.clemson.edu/all_dissertations/157


Clemson University

6. Tomblyn, Seth. EVALUATION OF HUMAN PROLACTIN, ITS ANTAGONIST, AND ANTAGONIST-BASED FUSION PROTEINS AS CHEMOPREVENTATIVE AND THERAPEUTIC AGENTS.

Degree: PhD, Microbiology, 2007, Clemson University

 Cancer is a collection of diseases with many different manifestations and is the second leading cause of death in the United States. Breast cancer accounts… (more)

Subjects/Keywords: Oncology

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Tomblyn, S. (2007). EVALUATION OF HUMAN PROLACTIN, ITS ANTAGONIST, AND ANTAGONIST-BASED FUSION PROTEINS AS CHEMOPREVENTATIVE AND THERAPEUTIC AGENTS. (Doctoral Dissertation). Clemson University. Retrieved from https://tigerprints.clemson.edu/all_dissertations/171

Chicago Manual of Style (16th Edition):

Tomblyn, Seth. “EVALUATION OF HUMAN PROLACTIN, ITS ANTAGONIST, AND ANTAGONIST-BASED FUSION PROTEINS AS CHEMOPREVENTATIVE AND THERAPEUTIC AGENTS.” 2007. Doctoral Dissertation, Clemson University. Accessed July 18, 2019. https://tigerprints.clemson.edu/all_dissertations/171.

MLA Handbook (7th Edition):

Tomblyn, Seth. “EVALUATION OF HUMAN PROLACTIN, ITS ANTAGONIST, AND ANTAGONIST-BASED FUSION PROTEINS AS CHEMOPREVENTATIVE AND THERAPEUTIC AGENTS.” 2007. Web. 18 Jul 2019.

Vancouver:

Tomblyn S. EVALUATION OF HUMAN PROLACTIN, ITS ANTAGONIST, AND ANTAGONIST-BASED FUSION PROTEINS AS CHEMOPREVENTATIVE AND THERAPEUTIC AGENTS. [Internet] [Doctoral dissertation]. Clemson University; 2007. [cited 2019 Jul 18]. Available from: https://tigerprints.clemson.edu/all_dissertations/171.

Council of Science Editors:

Tomblyn S. EVALUATION OF HUMAN PROLACTIN, ITS ANTAGONIST, AND ANTAGONIST-BASED FUSION PROTEINS AS CHEMOPREVENTATIVE AND THERAPEUTIC AGENTS. [Doctoral Dissertation]. Clemson University; 2007. Available from: https://tigerprints.clemson.edu/all_dissertations/171

.